Literature DB >> 18978304

Oncostatin M regulates secretoglobin 3A1 and 3A2 expression in a bidirectional manner.

Takeshi Tomita1, Atsushi Yamada, Masaaki Miyakoshi, Taketomo Kido, Faruk Sheikh, Achara Srisodsai, Atsushi Miyajima, Raymond P Donnelly, Shioko Kimura.   

Abstract

Secretoglobin (SCGB) 3A1 and 3A2 are members of the small molecular weight secretoglobin gene superfamily. SCGB3A1 is a tumor suppressor gene, whereas SCGB3A2 has anti-inflammatory properties. Both genes are mainly expressed in the lung and trachea in mice. Whether the expression and/or function of these two genes are related is not known. Here we show that the expression of SCGB3A1 and SCGB3A2 are bidirectionally regulated by oncostatin M (OSM) when examined in a mouse transformed Clara cell line (mtCC); SCGB3A1 is up-regulated by OSM, while SCGB3A2 is down-regulated in a time- and dose-dependent manner. OSM-activated STAT3/5, through binding to the STAT-binding element located at -201 to -209 bp in the mouse Scgb3a1 gene promoter, and the extracellular signal-regulated kinase (ERK)- and p38-mitogen-activated protein kinase (MAPK) pathways are responsible for the OSM-induced up-regulation of SCGB3A1 expression. On the other hand, the -113 to -273 bp region in the Scgb3a2 promoter appears to be responsible for the OSM induced down-regulation of the gene. No significant differences in the levels or patterns of specific DNA-binding proteins were found in the -113 to -273 bp region as determined by electrophoretic mobility shift assays. Neither the ERK- nor p38-MAPK pathways were involved in the OSM-induced reduction of Scgb3a2 promoter activity. These results suggest that OSM-induced suppression of SCGB3A2 expression is an indirect effect of OSM. Expression of the Clara cell marker, CYP2F2, was markedly decreased upon OSM treatment in parallel with the decrease of SCGB3A2 expression in mtCC cells. The differential regulation of Scgb3a1 and Scgb3a2 gene expression by OSM may explain the unique functions of these genes in the lung.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978304      PMCID: PMC2677441          DOI: 10.1165/rcmb.2008-0062OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  47 in total

1.  Interferon-gamma regulation of Clara cell gene expression: in vivo and in vitro.

Authors:  S M Magdaleno; G Wang; K J Jackson; M K Ray; S Welty; R H Costa; F J DeMayo
Journal:  Am J Physiol       Date:  1997-06

2.  Regulation of tissue inhibitor of metalloproteinase-1 in fibroblasts and acute phase proteins in hepatocytes in vitro by mouse oncostatin M, cardiotrophin-1, and IL-6.

Authors:  C D Richards; C Kerr; M Tanaka; T Hara; A Miyajima; D Pennica; F Botelho; C M Langdon
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

3.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  T-cell subset-specific expression of the IL-4 gene is regulated by a silencer element and STAT6.

Authors:  M Kubo; J Ransom; D Webb; Y Hashimoto; T Tada; T Nakayama
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  Mucin gene expression during differentiation of human airway epithelia in vitro. Muc4 and muc5b are strongly induced.

Authors:  S H Bernacki; A L Nelson; L Abdullah; J K Sheehan; A Harris; C W Davis; S H Randell
Journal:  Am J Respir Cell Mol Biol       Date:  1999-04       Impact factor: 6.914

6.  The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression.

Authors:  E Korzus; H Nagase; R Rydell; J Travis
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

7.  Distinct roles of oncostatin M and leukemia inhibitory factor in the development of primordial germ cells and sertoli cells in mice.

Authors:  T Hara; K Tamura; M P de Miguel; Y Mukouyama; H j Kim; H Kogo; P J Donovan; A Miyajima
Journal:  Dev Biol       Date:  1998-09-15       Impact factor: 3.582

8.  Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy.

Authors:  D S Postma; E R Bleecker; P J Amelung; K J Holroyd; J Xu; C I Panhuysen; D A Meyers; R C Levitt
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

9.  Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway.

Authors:  A Yoshimura; M Ichihara; I Kinjyo; M Moriyama; N G Copeland; D J Gilbert; N A Jenkins; T Hara; A Miyajima
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

10.  Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture.

Authors:  C D Richards; M Shoyab; T J Brown; J Gauldie
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

View more
  4 in total

1.  Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance.

Authors:  J N Jeyapalan; D A Mohamed Noor; S-H Lee; C L Tan; V A Appleby; J P Kilday; R D Palmer; E C Schwalbe; S C Clifford; D A Walker; M J Murray; N Coleman; J C Nicholson; P J Scotting
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

2.  Preclinical evaluation of human secretoglobin 3A2 in mouse models of lung development and fibrosis.

Authors:  Yan Cai; Melissa E Winn; John K Zehmer; William K Gillette; Jacek T Lubkowski; Aprile L Pilon; Shioko Kimura
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

Review 3.  The enigmatic cytokine oncostatin m and roles in disease.

Authors:  Carl D Richards
Journal:  ISRN Inflamm       Date:  2013-12-08

4.  Comparative Gene Signature of (-)-Oleocanthal Formulation Treatments in Heterogeneous Triple Negative Breast Tumor Models: Oncological Therapeutic Target Insights.

Authors:  Mohammed H Qusa; Khaldoun S Abdelwahed; Abu Bakar Siddique; Khalid A El Sayed
Journal:  Nutrients       Date:  2021-05-18       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.